D. Boral Capital Reaffirms "Buy" Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX - Get Free Report)'s stock had its "buy" rating reissued by analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $5.00 price target on the stock.

A number of other research firms have also weighed in on VNRX. StockNews.com initiated coverage on shares of VolitionRx in a research report on Friday, January 31st. They issued a "sell" rating on the stock. Benchmark reaffirmed a "hold" rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Price Performance

Shares of VNRX traded down $0.02 during mid-day trading on Thursday, reaching $0.58. 127,870 shares of the company's stock were exchanged, compared to its average volume of 101,305. The business's fifty day simple moving average is $0.62 and its 200-day simple moving average is $0.65. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.17. The stock has a market capitalization of $53.75 million, a PE ratio of -1.61 and a beta of 1.20.

Insider Activity at VolitionRx

In related news, CEO Cameron John Reynolds purchased 139,811 shares of VolitionRx stock in a transaction dated Monday, December 9th. The stock was bought at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the transaction, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the acquisition, the director now owns 617,085 shares in the company, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 358,266 shares of company stock worth $204,212 over the last three months. 12.80% of the stock is currently owned by corporate insiders.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC increased its holdings in VolitionRx Limited (NYSE:VNRX - Free Report) by 15.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 730,448 shares of the company's stock after buying an additional 95,900 shares during the period. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.09% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.